Covid-19 roundup: Pfizer/BioNTech’s Warp Speed deal means big money for two billionaire twins; Novavax lays out a rich smorgasbord of stock options for ... Phase II?
The Covid-19 drug and vaccine race has made a few biotech investors and executives quite a bit of cash, most notably Moderna CEO Stephané Bancel, who became a billionaire as Moderna’s stock quadrupled over the course of the pandemic. Other executives around the industry exercised stock options for a few or tens of millions of dollars.
No one, though, may have made more than a pair of billionaire German twins, Thomas and Andreas Struengmann, who in 2008 bankrolled the founding of a biotech that promised to make vaccines out of mRNA, called BioNTech. In recent years, the platform attracted major investors and partners, a $150 million IPO, and this winter, as Covid-19 spread, an expanded partnership with Pfizer to develop a Covid-19 vaccine.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.